Pokles hmotnosti o 19,3 % v 48. týždni: spoločnosť Hansoh prezentovala na EASD III. fázu štúdie o olatorepatide, duálnom funkčne selektívnom agonistovi receptorov GLP-1 a GIP

Olatorepatid (HS-20094), an internally developed biased dual GLP-1/GIP receptor agonist, was featured in connection with the European Association for the Study of Diabetes annual meeting in Milan, held September 28 to October 2, 2026. The provided excerpt contains no clinical efficacy, safety, regulatory, or financial data, limiting the immediate investment significance.